The Food and Drug Administration launched the Expedited Investigational New Drug Pilot program on Sept. 15, creating a faster regulatory pathway for experimental drugs to enter early-stage clinical trials in humans.
The FDA began accepting applications immediately upon the program’s launch, the agency said. The pilot is designed to compress the timeline from drug discovery to first-in-human trials, a process that has traditionally taken months or years of regulatory review.
The Expedited IND Pilot affects how quickly experimental therapies for cancer, rare diseases, neurological disorders and other serious conditions can begin testing in patients. For Americans awaiting breakthrough treatments, a shortened development timeline could mean earlier access to potentially life-saving therapies.
Under the standard Investigational New Drug process, drug developers must submit extensive preclinical data packages to the FDA and wait for agency review before enrolling patients in trials. The pilot streamlines portions of that process for qualifying applications, according to the FDA.
The reform targets the earliest and often most time-consuming phase of drug development, where promising laboratory compounds must clear regulatory hurdles before researchers can test whether they work in humans. Delays at this stage cascade through the entire development pipeline.
The biopharma industry has long advocated for faster IND processing, arguing that regulatory lag time slows innovation and delays patient access to new therapies. Patient advocacy groups have similarly pressed for reforms that accelerate clinical trial initiation for serious and life-threatening diseases.
The FDA said the pilot will be evaluated based on application volume, processing times and the quality of submissions received. Results will inform whether the expedited pathway becomes a permanent feature of the agency’s regulatory framework.
The program is open to all drug developers, including academic medical centers, biotech startups and large pharmaceutical companies. Detailed eligibility criteria and application instructions are available on the FDA’s website.